Ethcathinone (ETH-CAT, N-ethylcathinone) is a synthetic stimulant of the cathinone chemical class, structurally derived from cathinone — the principal active alkaloid in khat (Catha edulis) — through N-ethyl substitution. It is the N-ethyl analog of cathinone itself and an N-alkyl homolog of methcathinone, placing it among the simplest and most structurally straightforward members of the synthetic cathinone family.
ETH-CAT acts primarily as a dopamine and norepinephrine reuptake inhibitor, producing stimulant effects qualitatively similar to methcathinone and related compounds but generally considered to be of moderate potency within the cathinone class. The subjective experience is predominantly stimulant in character — increased energy, focus, mild euphoria, appetite suppression, and elevated heart rate — with limited entactogenic component, reflecting its minimal serotonergic activity. Users characterize ETH-CAT as a relatively "clean" cathinone stimulant with a relatively modest risk profile compared to high-potency pyrrolidine cathinones, though this comparison must be made carefully given the limited human research data available.
The primary risks of ETH-CAT are consistent with other cathinone stimulants: cardiovascular stress, compulsive redosing potential (though less severe than pyrrolidine cathinones), sleep disruption, and anxiety at higher doses. Community experience suggests ETH-CAT occupies a middle ground in the cathinone spectrum — not as compelling or intense as A-PVP or MDPV, but more potent and stimulant-directed than entactogenic cathinones like butylone. This positioning means it shares risks with both classes without the specific distinctive features of either.
ETH-CAT is substantially understudied relative to its use prevalence, and the absence of formal pharmacological characterization means that extrapolation from structurally related cathinones is the primary basis for harm reduction guidance.
Safety at a Glance
High Risk- Test Your Substance
- Cathinones in the research chemical market are frequently misrepresented. Use reagent testing to confirm the presence...
- Toxicity: Cardiovascular Effects ETH-CAT produces sympathomimetic cardiovascular effects through dopamine and norepinephrine re...
- Dangerous with: 25x-NBOH, 25x-NBOMe, Atropa belladonna, Datura, MDMA (+3 more)
- Overdose risk: Stimulant overdose from ETH-CAT is a medical emergency primarily involving cardiovascular and neu...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
insufflated
oral
Duration
insufflated
Total: 2 hrs – 3 hrsoral
Total: 3 hrs – 5 hrsHow It Feels
ETH-CAT, or ethcathinone, arrives with the brisk, no-nonsense onset typical of cathinone stimulants. Within fifteen to thirty minutes of insufflation or thirty to sixty minutes orally, a wave of alert energy begins to build. The mood lifts measurably. There is a subtle but genuine warmth in the chest and a desire to engage, to talk, to move, to do something. The stimulation is moderate in intensity, lacking the overwhelming rush of more potent cathinones but offering a clean, sociable energy that fits easily into everyday contexts.
At the peak, which settles in around forty-five minutes to an hour after onset, the experience is characterized by a gentle euphoria and increased sociability. Conversation flows more readily, social anxiety recedes, and there is a mild empathogenic quality that makes interactions feel warmer and more genuine than usual. The mind is alert and engaged without being frantic. Physical energy increases, and there is a desire to move, though not the compulsive restlessness that accompanies stronger stimulants. Music sounds better. The world feels marginally brighter and more interesting.
The body shows the standard signs of cathinone stimulation. Heart rate is elevated, pupils are somewhat dilated, and appetite is suppressed. There may be mild jaw tension and a slight dryness of the mouth. Body temperature rises marginally, and a light sweat may appear during physical activity. The overall physical load is light, and most users report feeling comfortable and functional throughout. Higher doses intensify the stimulation without proportionally increasing the euphoria, tipping the balance toward uncomfortable side effects.
The duration is relatively short, with the primary effects lasting two to four hours before a gentle taper back to baseline. The comedown is mild by cathinone standards, producing a slight tiredness and a subtle emotional flatness that resolves within a few hours. Sleep is usually achievable within four to six hours of the last dose. The overall impression is of a modest, serviceable stimulant that offers a pleasant social boost without the intensity, duration, or punishing aftermath of its more potent relatives. It is the kind of substance that may leave the user wondering whether the experience was strong enough to justify having taken anything at all.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(3)
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Cognitive & Perceptual Effects
Cognitive(8)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
Pharmacology
Mechanism of Action
The pharmacology of ETH-CAT has not been formally characterized in the scientific literature to the same degree as many other cathinones. Based on structural analysis and comparison with related compounds — particularly methcathinone and N-ethylamphetamine — ETH-CAT is believed to act primarily as a dopamine and norepinephrine reuptake inhibitor (NDRI).
The N-ethyl substitution (replacing the terminal N-H or N-methyl of methcathinone with N-ethyl) alters the compound's binding characteristics at monoamine transporters and modifies metabolic profile, but does not fundamentally change the mechanism from that of other simple cathinone stimulants.
Relative Activity at Monoamine Transporters
Like other simple cathinones, ETH-CAT is expected to have activity primarily at DAT and NET, with relatively limited SERT activity. This selectivity profile — predominantly dopaminergic and noradrenergic — produces the predominantly stimulant character of the experience and distinguishes it from the entactogenic MDxx-cathinone class.
Pharmacokinetics
ETH-CAT's pharmacokinetics are not well-characterized in published research. Based on the general cathinone pharmacokinetic profile and the beta-ketone modification present in all cathinones (which reduces lipophilicity and CNS penetration relative to the corresponding amphetamine), ETH-CAT likely has a duration of action in the 2–4 hour range. The beta-ketone group renders cathinones more polar and reduces blood-brain barrier permeability compared to amphetamines, typically resulting in somewhat lower CNS potency per dose despite similar peripheral pharmacological activity.
Comparisons
Methcathinone is a structurally close analog with extensive documentation; ETH-CAT is predicted to have a broadly similar but distinct pharmacological profile. The N-ethyl modification typically reduces potency somewhat compared to N-methyl (methcathinone) substitution at dopamine transporters.
Detection Methods
Standard Drug Panel Inclusion
Ethcathinone is a substituted cathinone (synthetic cathinone) that is not included on standard 5-panel or 10-panel immunoassay drug screens. Some extended panels (particularly those marketed for "bath salts" detection) may include cross-reactive antibodies for the cathinone class, but coverage is inconsistent. The structural relationship to amphetamine means some cathinones trigger the amphetamine channel on immunoassays, but this is compound-specific and unreliable for Ethcathinone.
Urine Detection
Ethcathinone and its metabolites can typically be detected in urine for 2 to 4 days following a single dose. Repeated or binge-pattern use may extend this window to 5 or more days. Primary metabolic pathways involve reduction of the beta-keto group, N-dealkylation, and hydroxylation. The resulting metabolites are excreted renally, often as glucuronide or sulfate conjugates.
Blood and Saliva Detection
Blood detection windows for Ethcathinone range from 12 to 48 hours depending on dose and individual metabolism. Plasma concentrations decline rapidly due to extensive distribution into tissues. Oral fluid testing can detect Ethcathinone for approximately 24 to 48 hours but is not commonly deployed for synthetic cathinones outside of specialized forensic settings.
Hair Follicle Detection
Hair analysis can detect synthetic cathinones including Ethcathinone for up to 90 days. Incorporation into the hair shaft follows standard pharmacokinetic principles for basic amines. However, most commercial hair testing panels do not specifically target Ethcathinone, requiring custom LC-MS/MS methods with appropriate reference standards.
Confirmatory Testing
Definitive identification of Ethcathinone requires instrumental analysis. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred method for synthetic cathinones due to their thermal lability, which can cause degradation during gas chromatography. GC-MS remains usable but may require derivatization for optimal sensitivity. Reference standards specific to Ethcathinone are necessary for quantitative confirmation.
Reagent Testing
Marquis reagent typically produces no reaction or a faint yellow-orange color with Ethcathinone. Mecke reagent may show no significant color change. Mandelin reagent can produce a yellow to brown reaction. The lack of strong, characteristic color reactions with common reagents makes cathinone identification by reagent testing alone unreliable. A combination of Marquis, Mecke, Mandelin, and Simon's reagents can help rule out other substance classes but cannot positively confirm Ethcathinone.
Interactions
| Substance | Status | Note |
|---|---|---|
| 25x-NBOH | Dangerous | — |
| 25x-NBOMe | Dangerous | — |
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDMA | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Dissociatives | Uncertain | — |
History
Chemical Background
Ethcathinone is derived directly from cathinone, the naturally occurring beta-ketone stimulant present in the khat plant, through simple N-ethylation. The khat plant has been used as a stimulant in East Africa and the Arabian Peninsula for centuries; its isolation and chemical modification began in the late 19th and early 20th centuries. The cathinone chemical class gained renewed attention in the 2000s and 2010s with the emergence of the designer drug market.
Appearance in NPS Markets
ETH-CAT was documented in European drug early warning systems in the early 2010s as part of the broader cathinone NPS wave. It appeared in forensic analyses of "bath salts" and research chemical products, typically as a relatively minor component compared to mephedrone, methylone, and later MDPV-class compounds.
Regulatory Status
ETH-CAT is controlled in numerous jurisdictions. In the European Union, it was identified in EMCDDA early warning system reports and subsequently controlled in various member states. The UK Psychoactive Substances Act 2016 effectively prohibited it by class, as it does all psychoactive substances not specifically exempted. US regulatory status depends on analog scheduling and state-level legislation.
Research Context
ETH-CAT has been characterized primarily through forensic and pharmacological studies examining the broader cathinone class. It is less prominently documented than more commercially significant cathinones like mephedrone or MDPV, reflecting its lesser market presence and lower clinical impact.
Harm Reduction
Test Your Substance
Cathinones in the research chemical market are frequently misrepresented. Use reagent testing to confirm the presence of a cathinone-class compound:
- Mecke and Marquis reagents can distinguish cathinone classes
- Fentanyl test strips are advisable given the prevalence of fentanyl in research chemical supplies
Dose Carefully
ETH-CAT is not fully characterized pharmacologically; treat it as potent until proven otherwise:
- Start with a test dose and wait for full onset before proceeding
- Use a milligram-accurate scale for dosing
Avoid Compulsive Redosing
Even for cathinones considered less compulsive than pyrrolidine analogs, the dopaminergic mechanism creates redosing pressure:
- Set a dose limit in advance
- Allow adequate time between doses (at least 90–120 minutes)
- Avoid using in contexts or emotional states that drive compulsive seeking
Dangerous Combinations
Research the Specific Batch
Individual batches of research chemicals can vary significantly in purity and potency. If purchasing ETH-CAT, consider community dosing reports from the same vendor/batch as a calibration guide, while treating all such reports with appropriate skepticism.
Toxicity & Safety
Cardiovascular Effects
ETH-CAT produces sympathomimetic cardiovascular effects through dopamine and norepinephrine reuptake inhibition: elevated heart rate, increased blood pressure, peripheral vasoconstriction. While the potency of these effects is believed to be moderate compared to high-potency pyrrolidine cathinones, they are dose-dependent and represent meaningful risk at higher doses or in individuals with pre-existing cardiovascular disease.
Compulsive Use Risk
While ETH-CAT is likely less compulsively driven than high-potency pyrrolidine cathinones (A-PVP, MDPV), the cathinone dopaminergic mechanism carries inherent reinforcing properties. The short-to-moderate duration of effects (2–4 hours) and the hedonic appeal of the stimulant effects create conditions for repeated dosing. Community accounts of cathinone comedowns apply to ETH-CAT — fatigue, dysphoria, and disrupted sleep follow extended use.
Psychiatric Effects
High-dose or extended use may produce anxiety, paranoia, and in extreme cases stimulant psychosis, consistent with other dopaminergic stimulants. This risk is substantially lower with ETH-CAT than with high-potency pyrrolidine cathinones but is not absent.
Unknown Risks
The limited formal research on ETH-CAT means that the full toxicological profile — particularly chronic and neurotoxic effects — is unknown. This uncertainty itself constitutes a significant risk.
Drug Interactions
- MAOIs: Contraindicated — risk of hypertensive crisis
- Other stimulants: Additive cardiovascular strain
- Alcohol: Masks stimulant toxicity warning signs
Addiction Potential
mildly addictive with a comparatively low potential for abuse
Overdose Information
Stimulant overdose from ETH-CAT is a medical emergency primarily involving cardiovascular and neurological toxicity.
Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.
Emergency response:
- Call emergency services immediately
- Keep the person cool (remove excess clothing, apply cool water)
- If seizures occur, protect the head and clear the area of hard objects
- If the person loses consciousness, place in recovery position
- Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionals
Prevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 2 - 3 days |
| Zero | 3-5 days |
Cross-tolerances
Legal Status
ETH-CAT is currently a grey area compound within many parts of the world. People may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.
Brazil: On September 7, 2018, all cathinone analogues are controlled substances considered illegal to possess, use and distribute. This was made possible due to a blanket ban law appended to Portaria SVS/MS nº 344.
China: As of October 2015 Ethylcathinone is a controlled substance in China.
Denmark: Ethcathinone, along with mephedrone and flephedrone, was banned in Denmark on December 18, 2008.
Germany: Ethylcathinone is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of July 26, 2012. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Poland: Ethylcathinone is a Group I-P controlled substance.
Sweden: Ethylcathinone in list I.
Switzerland: Ethylcathinone is a controlled substance specifically named under Verzeichnis E.
United Kingdom: Ethylcathinone is a Class B drug in the United Kingdom as a result of the cathinone catch-all clause.
United States: Ethylcathinone may be considered to be an analogue of amphetamine under the Federal Analogue Act.The Federal Analogue Act, 21 U.S.C. § 813, is a section of the United States Controlled Substances Act, allowing any chemical "substantially similar" to an illegal drug (in Schedule I or II) to be treated as if it were also in Schedule I or II, but only if it is intended for human consumption.
Responsible use
Stimulants
Substituted cathinone
Amphetamine
Ethcathinone (Wikipedia)
Ethcathinone (Erowid Vault)
ETH-CAT (Isomer Design)
Experience Reports (1)
Tips (3)
Start low with ETH-CAT and wait for full onset before redosing. Stimulant redosing extends duration and side effects more than it extends euphoria, while adding cardiovascular strain. Set a firm limit before you start.
Test ETH-CAT with appropriate reagent kits and fentanyl test strips. Stimulant supplies have increasingly been found contaminated with fentanyl, which has caused a surge in overdose deaths among stimulant users.
Have a landing plan for the ETH-CAT comedown. Prepare food, melatonin or magnesium, and a comfortable environment in advance. Avoid using depressants to manage the comedown as this creates polydrug dependency patterns.
See Also
References (4)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- PubChem: ETH-CAT
PubChem compound page for ETH-CAT (CID: 458519)
pubchem - ETH-CAT - TripSit Factsheet
TripSit factsheet for ETH-CAT
tripsit - ETH-CAT - Wikipedia
Wikipedia article on ETH-CAT
wikipedia